Table 2:

Procedural details and clinical outcomes of the 2 groups

Overall SamplePSM Sample
AT Group (n = 40)SRT Group (n = 69)OR (95% CI)PAT Group (n = 30)SRT Group (n = 30)OR (95% CI)P
eTICI 2b–3, n (%)40 (100)56 (81.2)1.23 (1.10–1.38).00230 (100)27 (90.0)1.11 (0.99–1.25).237
eTICI 2c–3, n (%)34 (85.0)38 (55.1)4.62 (1.72–12.43).00126 (86.7)15 (50.0)6.50 (1.82–23.21).006
eTICI 3, n (%)29 (72.5)32 (46.4)3.05 (1.32–7.06).00822 (73.3)11 (36.7)4.75 (1.58–14.25).004
First pass to eTICI 2b–3, n (%)10 (25.0)15 (21.7)1.20 (0.48–3.00).6969 (30.0)9 (30.0)1.00 (0.33–3.02).999
First pass to eTICI 2c–3, n (%)10 (25.0)12 (17.4)1.58 (0.61–4.01).3409 (30.0)6 (20.0)3.05 (1.00–3.93).044
First pass to eTICI 3, n (%)8 (20.0)11 (15.9)1.32 (0.48–3.61).5908 (26.7)5 (16.7)1.82 (0.52–6.38).347
No. passes of thrombectomy, median (IQR)2 (2–3.7)3 (2–4)NA.9002 (1–3)2.5 (1–3)NA.367
Rescue treatment, n (%)6 (15.0)8 (11.6)1.35 (0.43–4.20).6085 (16.7)6 (20.0)0.80 (0.22–2.97).739
PRT, median (IQR) (min)46 (24–68)83 (55–120)NA.00138 (22–56)69 (45–120)NA.001
Onset to reperfusion time, median (IQR) (min)355 (222–550)337 (264–420)NA.900249 (205–391)344 (248–450)NA.145
Use of rtPA, n (%)12 (30.0)33 (47.8)0.47 (0.21–1.07).06811 (36.7)15 (50.0)0.58 (0.19–1.59).297
Administration of GPI, n (%)2 (5.0)10 (14.5)0.31 (0.06–1.50).2271 (3.3)3 (10.0)0.31 (0.03–3.17).605
Balloon angioplasty, n (%)1 (2.5)2 (2.9)0.86 (0.08–9.78).9991 (3.3)2 (6.7)0.48 (0.04–5.63).999
Stent placement, n (%)0 (0)5 (7.2)0.33 (0.04–2.91).1560 (0)2 (6.7)1.07 (0.97–1.18).492
IV heparin, n (%)28 (70.0)36 (52.2)2.14 (0.94–4.88).06819 (63.3)15 (50.0)1.73 (0.62–4.85).297
mRS score 0–1 at 90 days, n (%)13 (32.5)15 (21.7)1.73 (0.72–4.16).21511 (36.7)5 (16.7)2.90 (0.86–9.75).080
mRS score 0–2 at 90 days, n (%)17 (42.5)22 (31.9)1.92 (0.86–4.25).26515 (50.0)9 (30.0)2.33 (0.81–6.73).114
mRS score 3–5 at 90 days, n (%)17 (42.5)35 (50.7)0.72 (0.33–1.57).40710 (33.3)16 (53.3)0.44 (0.15–1.24).118
  • Note:—NA indicates not applicable; GPI, glycoprotein IIb/IIIa receptor inhibitor.